Please assess the completion status of the following clinical trial:

Trial Title: Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 year-old~2. Had cardiovascular disease which needed clopidogrel and aspirin~3. Stable enough for gastroscopy~Exclusion Criteria:~1. Gastroscopy revealed peptic ulcer~2. Had contraindication for gastroscopy~3. Not allowed for gastroscopy by cardiologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Repamipide (Type: ACTIVE_COMPARATOR): Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
- placebo (Type: PLACEBO_COMPARATOR): A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.

Based on this trial design, predict the completion outcome and termination type (if applicable).